Ceretrieve

Company Overview

Snapshot

Founded in December 2016 by Eytan Jaffe and Ronen Jaffe, Ceretrieve operates with 11–50 employees. The company has raised $1.5 million across two funding rounds from four investors. In October 2025, Ceretrieve secured funding from 4T Ventures.

Business overview

Ceretrieve is a medical device company focused on developing solutions for ischemic stroke treatment. The company's core product is CathTrap, a neurothrombectomy system designed with integrated embolic protection. CathTrap is an aspiration catheter featuring an expandable soft tip that can enlarge its diameter to match clot size, providing powerful aspiration force to extract and ingest clots while preventing distal embolization. Ceretrieve serves the healthcare industry, specifically targeting neurosurgery and cardiology markets with its medical devices for stroke intervention.

Strategic signal

In January 2021, Amir Belson was appointed as Ceretrieve's Chairman following a funding round. This leadership addition signals a strategic move to strengthen the company's governance and potentially accelerate its clinical and commercial development, leveraging Belson's expertise in the healthcare sector.

Company Intelligence Q&A

What is Ceretrieve's primary product?

Ceretrieve's primary product is CathTrap, a neurothrombectomy system with integrated embolic protection designed for ischemic stroke endovascular treatment. It features an aspiration catheter with an expandable soft tip.

When was Ceretrieve founded and by whom?

Ceretrieve was founded in December 2016 by co-founders Eytan Jaffe and Ronen Jaffe.

Who was appointed Chairman of Ceretrieve in January 2021?

Amir Belson was appointed as Ceretrieve's Chairman in January 2021, following a funding round that included investment from.

What is the current product stage of Ceretrieve's technology?

Ceretrieve's product, CathTrap, is currently in the Clinical Trial stage, as indicated by the company's product stage information.